# Pillar Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pillar-biosciences

- Industry: Biotechnology
- Headquarters: Natick, US
- Website: www.pillarbiosci.com/
- Total disclosed funding: $71M
- Latest round: Series D (May 27, 2025)
- Investors on record: 3

## About

Pillar Biosciences, Inc. is a US-based company specializing in next-generation sequencing (NGS) solutions, focusing on diagnostic technologies that support clinical treatment decisions across various healthcare settings.Founded in 2014 and headquartered in Natick, US, Pillar Biosciences develops innovative NGS solutions aimed at enhancing diagnostic capabilities. The company has undergone strategic pivots to focus on its core products and has successfully raised USD 34.5 mn in Series D funding as part of its growth strategy. The founder, Zhaohui Wang, has a background in biotechnology, contributing significant expertise to the company’s direction. Pillar Biosciences has engaged in a total of 5 deals, with the most recent funding round occurring on May 27, 2025, supported by investors including Illumina, Inc. and Soleus Capital, leading to a current valuation of USD 271.84 mn.Pillar Biosciences specializes in next-generation sequencing (NGS) solutions, primarily focusing on diagnostic technologies that enhance treatment decisions in clinical settings. The company’s flagship products include the VersaTile™, SLIMamp®, and PiVAT® technologies, which collectively offer a comprehensive solution for NGS laboratories. These products enable actionable, reliable, and rapid clinical results, facilitating timely diagnostic decisions by healthcare providers. The primary end users of these products are medical laboratories and clinicians in hospitals and healthcare facilities across various geographical markets, including North America, Europe, and parts of Asia, addressing a broad spectrum of oncological and genetic testing needs.Pillar Biosciences generates revenue through direct sales and partnerships with healthcare providers and laboratories that utilize its NGS diagnostic technologies. The company’s revenue model is built around the sale of its proprietary products, which may involve one-time transactions or ongoing agreements for support and consumables. For instance, clients may purchase the oncoReveal® CDx Pan-Cancer Solid Tumor IVD Kit as a standalone product for specific diagnostic needs. Additionally, Pillar Biosciences engages in co-marketing agreements, such as the one established with Hamilton Company, to leverage combined offerings in the marketplace, facilitating wider distribution and accessibility of its technologies. Such partnerships enhance the company’s revenue potential by expanding its reach and client base within the healthcare sector.Pillar Biosciences plans to utilize the recent funding of USD 34.5 mn from its Series D round to enhance its commercial activities, expand its workforce, and improve its infrastructure, which will support biopharma partnerships and increase the distribution of its clinical testing kits. The company is focusing on designing and launching new products to meet the evolving needs of the market and aims to expand its footprint in new geographic regions, specifically targeting additional markets across Europe and Asia by the end of 2026.

## Funding rounds

- Series D, May 27, 2025, $35M — Illumina, Inc., Soleus Capital
- Series C, Feb 24, 2020, $18M — ORI Capital
- Series A, May 11, 2016, $18M — ORI Capital

## Investors

- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series A, Series C
- Illumina, Inc. — Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series D